



## ASX ANNOUNCEMENT

14 June 2007

### **Raises in Excess of \$30 million in Private Share Placement**

HeartWare is pleased to announce that it has conducted a private share placement for which it has received commitments for in excess of \$30 million from institutional and sophisticated investors in Australia, the United States and Europe, offered under Regulation S of the Securities Act of 1933, as amended (the “**Act**”) and under Regulation D of the Act in the United States (collectively, the “**Share Placement**”). Shares issued under the Share Placement will be priced at A\$0.60 per share (the “**Securities**”).

The Share Placement has been underpinned by thirteen institutional investors, including ten from Australia and three from the United States. The US institutions account for approximately one-third of the total Share Placement.

The proceeds of the capital raising will be used primarily to fund the clinical development and commercialization of HeartWare’s HVAD<sup>TM</sup> Left Ventricular Assist Device.

Completion of the Share Placement is subject to shareholder approval, which will be sought at an Extraordinary General Meeting of shareholders, scheduled for 26 July 2007. The Company expects to distribute the Notice of Meeting to shareholders on or about 22 June 2007.

#### **Share Purchase Plan**

HeartWare intends to provide a Share Purchase Plan (“**SPP**”) to its Australian shareholders at A\$0.60 per share, being the same issue price as the Securities offered under the Share Placement (the “**SPP Shares**”).

Under the SPP, Australian shareholders may apply for shares in the Company up to a maximum of A\$5,000 per shareholder.

The Record Date for participation in the SPP has been set at 4.00pm (AEST) on Wednesday, 13 June 2007. Offer documents for the SPP will be forwarded to eligible shareholders on or about Wednesday, 20 June 2007.

*The Securities and SPP Shares described herein have not been registered under the Act in reliance on exemptions from registration under Regulation S and Regulation D of the Act, and as a result the Securities and SPP Shares may not be resold into the United States of America except pursuant to registration under the Act or an exemption therefrom. This notice does not constitute an offer of any Securities or SPP Shares for sale.*



### **About HeartWare**

HeartWare is developing a family of proprietary circulatory assist devices to treat patients with heart failure. HeartWare's lead investigatory product, the HVAD™ device, is currently progressing through an international clinical trial. With a volume of 45cc, the HVAD™ device is the smallest "3rd generation" pump and the only full output device implantable routinely within the thoracic cavity.

HeartWare's miniaturization platform enables the development of smaller devices, potentially implantable by minimally invasive surgical techniques. Pre-clinical studies are underway for HeartWare's MVAD™ device, a pump one-third the size of the HVAD™ device. HeartWare's IV-VAD, a pump one-tenth the size of the HVAD™ device, is at early prototype stage.

For further information:

[www.heartware.com.au](http://www.heartware.com.au)

Howard Leibman

Director Corporate Development

HeartWare Limited

+61 2 8215 7604 / 0402 440644